1. Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study.
- Author
-
Zhou N, Hua Y, Ge Y, Wang Q, Wang C, He J, Zhao L, Yu S, Yan J, Zhao L, Li L, and Bai C
- Subjects
- Humans, Male, Middle Aged, Female, Aged, Adult, Esophagectomy, Treatment Outcome, Neoplasm Staging, Neoadjuvant Therapy methods, Esophageal Squamous Cell Carcinoma therapy, Esophageal Squamous Cell Carcinoma drug therapy, Esophageal Squamous Cell Carcinoma mortality, Esophageal Squamous Cell Carcinoma pathology, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Esophageal Neoplasms drug therapy, Esophageal Neoplasms mortality, Esophageal Neoplasms therapy, Esophageal Neoplasms pathology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects
- Abstract
Background: The application of neoadjuvant immunotherapy in the treatment of esophageal cancer needs further exploration. This study aimed to investigate the safety and effectiveness of tislelizumab, an anti-PD-1 antibody, combined with chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (LA-ESCC)., Methods: In this phase II study, patients with clinical stages of II-IVA (T3-T4 and/or node positive) potentially resectable LA-ESCC were enrolled. Patients received neoadjuvant tislelizumab and chemotherapy every 3 weeks for 4 cycles before surgery and adjuvant tislelizumab for 9 months. The primary endpoint was pathological complete response (pCR) rate. Secondary endpoints included R0 resection, disease free survival (DFS), adverse events (AE), and biomarkers for predicting efficacy., Results: The study included 30 patients. 25 patients completed neoadjuvant chemoimmunotherapy and underwent surgery, 96% with R0 resection. The pCR and MPR rate was 44% and 52%. The 6-month and 1-year DFS rate was 100% and 75.3%. 43.3% patients experienced severe (grade 3-4) treatment-related adverse events (TRAEs) and 5 patients developed severe immune-related adverse events (irAEs). Further exploration found that a group of peripheral lymphocyte subsets increased significantly after 2 cycles of neoadjuvant therapy in patients who achieved pCR, suggesting the importance of dynamic monitoring of circulating lymphocyte., Conclusions: The combination of perioperative tislelizumab and neoadjuvant chemotherapy has achieved an encouraging pCR rate and demonstrated a manageable safety profile in patients with potentially resectable ESCC., Clinical Trial Registration: https://www.chictr.org.cn/, identifier ChiCTR2100043772., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Zhou, Hua, Ge, Wang, Wang, He, Zhao, Yu, Yan, Zhao, Li and Bai.)
- Published
- 2024
- Full Text
- View/download PDF